For instance, it is unknown whether the PD‐1/PD‐L1 inhibitors actually prolong the overall survival (OS) or progression‐free survival (PFS) and whether the HPV status is a predictive factor of efficacy for PD‐1/PD‐L1 targeted therapy in head and neck cancer. The gene discussed is CD274; the disease is head and neck cancer.